False Negative Rates of BPP and Modified BPP
Both the biophysical profile (BPP) and modified biophysical profile (mBPP) have exceptionally low false-negative rates of approximately 0.8 per 1,000 tests (or <1 in 1,000), meaning a normal test result is highly reassuring that stillbirth will not occur within the following week. 1
What These Numbers Mean Clinically
The false-negative rate represents the risk of stillbirth occurring within 7 days of a normal test result. These remarkably low rates translate to:
- Negative predictive value >99.9% for both tests 1
- A normal BPP or mBPP strongly predicts fetal well-being in high-risk pregnancies
- The likelihood of missing a compromised fetus is extremely small when testing is normal
Specific Data from Large Studies
For the BPP:
- In a study of 44,828 BPPs, the stillbirth rate within 1 week of a normal test was only 0.8 per 1,000 1
- In another series of 19,221 high-risk pregnancies, the false-negative rate was 0.726 per 1,000 2
- A separate study of 4,148 fetuses showed a false-negative rate of 0.7 per 1,000 3
For the mBPP:
- The false-negative rate is "extremely low, similar to that of a normal BPP at <1 in 1,000" 1
- A prospective study from 1990-1994 reported a false-negative rate of 0.8 per 1,000 women tested 4
- Five randomized trials involving 2,974 high-risk patients found no significant difference in perinatal deaths between BPP and mBPP 1
Clinical Implications
What Makes These Tests Reliable
Both tests perform comparably in predicting fetal survival, but they assess different aspects of fetal physiology:
- BPP components (fetal breathing, movement, tone, amniotic fluid) reflect acute and chronic fetal status
- mBPP (NST + amniotic fluid index) combines immediate oxygenation assessment with chronic placental function 1
Important Caveats
These tests cannot predict acute catastrophic events:
- Placental abruption
- Cord accidents
- Other sudden-onset complications 1
The false-negative rate applies only when:
- Testing is performed in high-risk pregnancies where it's indicated 1
- Results are interpreted within the 7-day window before delivery
- Testing frequency is appropriate (typically weekly or twice-weekly) 1
The False-Positive Problem
While false-negative rates are reassuringly low, both tests have higher false-positive rates (identifying compromise when the fetus is actually healthy):
- 60% of patients delivered for abnormal antepartum tests had no evidence of fetal compromise 4
- False-positive results led to preterm delivery in 1.5% of those tested before term 4
- This creates a clinical dilemma: balancing the risk of missing true compromise against causing iatrogenic prematurity 1
Practical Application
For high-risk pregnancies:
- A normal BPP or mBPP provides strong reassurance for at least the next week
- Testing should typically begin at 32-34 weeks (earlier if indicated)
- Weekly or twice-weekly surveillance is standard, though not rigorously evidence-based 1
For low-risk pregnancies:
- Routine antenatal testing is not recommended as it provides no benefit and may increase unnecessary interventions 1
When tests are abnormal:
- Before term: weigh risks of prematurity against risks of continued pregnancy
- At term: abnormal results typically indicate delivery 1
The exceptionally low false-negative rates make both the BPP and mBPP valuable tools for reassurance in appropriately selected high-risk pregnancies, though clinicians must remain aware that no test can predict all causes of stillbirth.